239 (PB119) - Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations
| Autor: | Ng, P.Y., Han, Y.C., Shin Ogawa, L., Schulz, R., Yang, S.N., Jewett, I., Ishiyama, N., Romashko, D., Salomatov, A., Thakur, S., Lucas, M., Lin, T.A., Buck, E. |
|---|---|
| Zdroj: | In European Journal of Cancer October 2022 174 Supplement 1:S86-S86 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect